A prominent player in genomic services and histopathology diagnostics has announced a strategic acquisition aimed at enhancing its capabilities. Source BioScience UK Ltd recently finalized the purchase of Cambridge Clinical Laboratories (CCL), a renowned provider of personalized healthcare testing solutions. This move strengthens Source BioScience's diagnostic portfolio by incorporating CCL’s advanced clinical lab facilities and specialized expertise, offering comprehensive testing options for both preclinical and clinical research phases.
Cambridge Clinical Laboratories is celebrated for its diverse range of personalized healthcare diagnostic services, which include oncology, virology, men's health, gastroenterology, and fertility testing. These services cater to both NHS clients and international private customers. By integrating CCL into its operations, Source BioScience enhances its existing genomics and multiomics capabilities, providing a full spectrum of laboratory services. This expansion allows researchers to navigate the entire development process—from R&D to clinical trials—with one trusted partner, minimizing resource demands and ensuring data consistency.
All employees and assets from CCL will transition to Source BioScience's upgraded clinical facility at Vision Park. The new site boasts significantly expanded laboratory capacity, enabling the company to not only enhance current offerings but also explore future innovations. Furthermore, this merger fosters greater collaboration between genomics and clinical services teams, delivering deeper insights to clients.
Jay LeCoque, Chairman and CEO of Source BioScience, expressed enthusiasm about welcoming CCL into their organization. He highlighted that CCL’s recognized expertise aligns perfectly with Source BioScience's mission to offer complete service packages. With the investment in state-of-the-art clinical lab facilities and talented personnel, the company anticipates tapping into broader market opportunities within clinical diagnostics.
Tony Cooke, former CEO and CSO of Cambridge Clinical Laboratories, praised the partnership. He noted that Source BioScience is an established leader in the biopharmaceutical sector, known for delivering valuable data-driven insights. Joining forces with Source BioScience presents an opportunity to combine the strengths of both organizations, accelerating access to cutting-edge research services and facilitating faster delivery of innovative therapies to patients.
The financial specifics of the acquisition remain undisclosed. Nonetheless, this strategic alliance positions Source BioScience as a formidable entity capable of supporting clients throughout all stages of their programs, while simultaneously expanding its influence in the clinical diagnostics domain.